PE20220570A1 - Anticuerpo anti-epha4 humano - Google Patents
Anticuerpo anti-epha4 humanoInfo
- Publication number
- PE20220570A1 PE20220570A1 PE2021002077A PE2021002077A PE20220570A1 PE 20220570 A1 PE20220570 A1 PE 20220570A1 PE 2021002077 A PE2021002077 A PE 2021002077A PE 2021002077 A PE2021002077 A PE 2021002077A PE 20220570 A1 PE20220570 A1 PE 20220570A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- human anti
- heavy chain
- Prior art date
Links
- 150000001413 amino acids Chemical group 0.000 abstract 6
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UN ANTICUERPO QUE SE UNE A EphA4 QUE COMPRENDE CADENAS PESADA Y LIGERA, LAS CUALES COMPRENDEN: A) UNA CDR1 DE CADENA PESADA QUE CONSISTE EN LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 44, B) UNA CDR2 DE CADENA PESADA QUE CONSISTE EN LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 27, C) UNA CDR3 DE CADENA PESADA QUE CONSISTE EN LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 28, D) UNA CDR1 DE CADENA LIGERA QUE CONSISTE EN LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 29, E) UNA CDR2 DE CADENA LIGERA QUE CONSISTE EN LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 30, Y F) UNA CDR3 DE CADENA LIGERA QUE CONSISTE EN LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 31. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019122982 | 2019-07-01 | ||
| PCT/JP2020/025465 WO2021002312A1 (ja) | 2019-07-01 | 2020-06-29 | 抗ＥｐｈＡ４抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220570A1 true PE20220570A1 (es) | 2022-04-20 |
Family
ID=74066003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021002077A PE20220570A1 (es) | 2019-07-01 | 2020-06-29 | Anticuerpo anti-epha4 humano |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10947313B2 (es) |
| EP (1) | EP3995582A4 (es) |
| JP (2) | JP6979147B2 (es) |
| KR (1) | KR20220027825A (es) |
| CN (2) | CN117398459A (es) |
| AR (1) | AR119303A1 (es) |
| AU (1) | AU2020300205A1 (es) |
| BR (1) | BR112021025161A2 (es) |
| CA (1) | CA3139398A1 (es) |
| CL (1) | CL2021003326A1 (es) |
| CO (1) | CO2021016588A2 (es) |
| IL (1) | IL287828A (es) |
| JO (1) | JOP20210333A1 (es) |
| MA (1) | MA56466A (es) |
| MX (1) | MX2021015298A (es) |
| MY (1) | MY207780A (es) |
| NZ (1) | NZ783106A (es) |
| PE (1) | PE20220570A1 (es) |
| PH (1) | PH12021553090A1 (es) |
| SG (1) | SG11202112433VA (es) |
| TW (3) | TWI808882B (es) |
| UA (1) | UA129772C2 (es) |
| WO (1) | WO2021002312A1 (es) |
| ZA (1) | ZA202108836B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12227567B2 (en) | 2017-07-25 | 2025-02-18 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| NZ783106A (en) | 2019-07-01 | 2025-08-29 | Eisai R&D Man Co Ltd | Anti-epha4 antibody |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| TW202241503A (zh) * | 2020-12-24 | 2022-11-01 | 日商衛材R&D企管股份有限公司 | 肌肉萎縮性側索硬化症之治療用醫藥組合物 |
| TW202323286A (zh) * | 2021-11-11 | 2023-06-16 | 日商衛材R&D企管股份有限公司 | 抗EphA4抗體 |
| WO2025151607A1 (en) * | 2024-01-10 | 2025-07-17 | Santa Ana Bio, Inc. | Methods and compositions for treating autoimmune, allergic and inflammatory diseases |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1094731A (en) | 1911-06-06 | 1914-04-28 | Lucien Linden | Oxidizing process. |
| CA1339413C (en) | 1988-06-24 | 1997-09-02 | Junichi Miyazaki | Exogenous gene expression vector containing chick .beta.-actin gene promoter |
| JP2824433B2 (ja) | 1988-12-09 | 1998-11-11 | 財団法人化学及血清療法研究所 | 新規なハイブリッドプロモーターおよびこれを組み込んだ外来遺伝子発現用ベクター |
| JP3680114B2 (ja) | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
| US5902732A (en) | 1995-10-04 | 1999-05-11 | Cytoscan Sciences Llc | Drug screening process measuring changes in cell volume |
| US20020068361A1 (en) | 1997-04-08 | 2002-06-06 | Douglas Clary | Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner |
| AU6887698A (en) | 1997-04-08 | 1998-10-30 | Sugen, Inc. | Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases |
| US5876946A (en) | 1997-06-03 | 1999-03-02 | Pharmacopeia, Inc. | High-throughput assay |
| US20060241074A1 (en) | 2001-08-14 | 2006-10-26 | The General Hospital Corporation | Methods for treatment of pain |
| EP1478772A2 (en) | 2001-08-14 | 2004-11-24 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| US20070026409A1 (en) | 2001-08-14 | 2007-02-01 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| JP2003169699A (ja) | 2001-12-10 | 2003-06-17 | Japan Science & Technology Corp | 特異的γプロテアーゼ阻害剤のスクリーニング方法 |
| JP2004000060A (ja) | 2002-05-31 | 2004-01-08 | Otsuka Pharmaceut Co Ltd | アミロイドβ産生に影響を与える化合物のスクリーニング方法 |
| WO2004028551A1 (en) | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| HRP20050461A2 (en) | 2002-11-26 | 2005-08-31 | Pharmacia & Upjohn Company Llc | Soluble notch-based substrates for gamma secretase and methods and compositions for using same |
| US7604799B2 (en) | 2003-06-06 | 2009-10-20 | Medimmune, Llc | EphA4 Antibodies |
| CN1878865A (zh) | 2003-11-10 | 2006-12-13 | 财团法人大阪产业振兴机构 | 无细胞Notch切割分析方法以及药物筛选方法 |
| US20070253954A1 (en) | 2004-02-27 | 2007-11-01 | Oncotherapy Science, Inc. | Epha4 As Therapeutic Target Of Prc And Pdaca |
| JP5094395B2 (ja) | 2004-09-08 | 2012-12-12 | ザ ユニバーシティー オブ クイーンズランド | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
| EP1662259A1 (en) | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
| GB0427023D0 (en) | 2004-12-09 | 2005-01-12 | Merck Sharp & Dohme | Assay method |
| WO2007102383A1 (en) | 2006-02-28 | 2007-09-13 | Oncotherapy Science, Inc. | Methods for damaging cells using effector functions of anti-epha4 antibodies |
| EP1947193A1 (en) | 2007-01-17 | 2008-07-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Screening method for anti-diabetic compounds |
| ATE546543T1 (de) | 2007-06-08 | 2012-03-15 | Eisai R&D Man Co Ltd | Screening-verfahren mit verwendung des neuen substrats epha4 für gamma-sekretase |
| EP2183598A1 (en) | 2007-07-13 | 2010-05-12 | Elan Pharmaceuticals Inc. | Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase |
| EP2177623A4 (en) | 2007-07-19 | 2010-12-29 | Eisai R&D Man Co Ltd | SCREENING METHOD USING C-MET, A NEW SUBSTRATE FOR GAMMA SECRETASE |
| WO2009017234A1 (ja) | 2007-08-01 | 2009-02-05 | Eisai R & D Management Co., Ltd. | γ-セクレターゼの新規基質c-Retを利用したスクリーニング方法 |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| US20090163594A1 (en) | 2007-10-31 | 2009-06-25 | Elan Pharmaceuticals, Inc. | Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors |
| JP5580598B2 (ja) | 2007-11-15 | 2014-08-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | γ−セクレターゼの新規基質ＥｐｈＡ７を利用したスクリーニング方法 |
| US7892769B2 (en) | 2007-11-30 | 2011-02-22 | Eisai R&D Management Co., Ltd. | Processing of EphA4 polypeptide by γ-secretase activity |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| JP2010285413A (ja) | 2009-06-10 | 2010-12-24 | Univ Of Melbourne | 治療用途 |
| EP2260864A1 (en) | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
| EP2653552B1 (en) | 2010-12-17 | 2016-10-19 | Eisai R&D Management Co., Ltd. | SCREENING METHOD USING GELATINASE-MEDIATED EphA4 CLEAVAGE REACTION AS AN INDICATOR |
| EP2703814B1 (en) | 2011-04-25 | 2017-11-01 | Eisai R&D Management Co., Ltd. | Method for detecting neurological disease associated with cognitive dysfunction by measuring epha4 extracellular domain |
| GB201107996D0 (en) | 2011-05-13 | 2011-06-29 | Vib Vzw | EphA4 is a diease modifier in motor neuron disease |
| JP6811706B2 (ja) | 2014-07-31 | 2021-01-13 | ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー | Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用 |
| EP3381941B1 (en) * | 2015-09-08 | 2020-11-11 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| NZ783106A (en) | 2019-07-01 | 2025-08-29 | Eisai R&D Man Co Ltd | Anti-epha4 antibody |
-
2020
- 2020-06-29 NZ NZ783106A patent/NZ783106A/en unknown
- 2020-06-29 TW TW111133484A patent/TWI808882B/zh active
- 2020-06-29 CA CA3139398A patent/CA3139398A1/en active Pending
- 2020-06-29 SG SG11202112433VA patent/SG11202112433VA/en unknown
- 2020-06-29 UA UAA202106526A patent/UA129772C2/uk unknown
- 2020-06-29 MX MX2021015298A patent/MX2021015298A/es unknown
- 2020-06-29 US US16/915,412 patent/US10947313B2/en active Active
- 2020-06-29 CN CN202311449611.XA patent/CN117398459A/zh active Pending
- 2020-06-29 MY MYPI2021006929A patent/MY207780A/en unknown
- 2020-06-29 PE PE2021002077A patent/PE20220570A1/es unknown
- 2020-06-29 EP EP20834769.0A patent/EP3995582A4/en active Pending
- 2020-06-29 JO JOP/2021/0333A patent/JOP20210333A1/ar unknown
- 2020-06-29 PH PH1/2021/553090A patent/PH12021553090A1/en unknown
- 2020-06-29 KR KR1020217038552A patent/KR20220027825A/ko active Pending
- 2020-06-29 CN CN202080039114.0A patent/CN113906050B/zh active Active
- 2020-06-29 JP JP2021519890A patent/JP6979147B2/ja active Active
- 2020-06-29 AU AU2020300205A patent/AU2020300205A1/en active Pending
- 2020-06-29 AR ARP200101834A patent/AR119303A1/es unknown
- 2020-06-29 MA MA056466A patent/MA56466A/fr unknown
- 2020-06-29 BR BR112021025161A patent/BR112021025161A2/pt unknown
- 2020-06-29 TW TW109121908A patent/TWI779307B/zh active
- 2020-06-29 TW TW112123862A patent/TWI866304B/zh active
- 2020-06-29 WO PCT/JP2020/025465 patent/WO2021002312A1/ja not_active Ceased
-
2021
- 2021-01-08 US US17/145,001 patent/US11136400B2/en active Active
- 2021-11-03 IL IL287828A patent/IL287828A/en unknown
- 2021-11-09 ZA ZA2021/08836A patent/ZA202108836B/en unknown
- 2021-11-12 JP JP2021184594A patent/JP7072114B2/ja active Active
- 2021-12-07 CO CONC2021/0016588A patent/CO2021016588A2/es unknown
- 2021-12-13 CL CL2021003326A patent/CL2021003326A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220570A1 (es) | Anticuerpo anti-epha4 humano | |
| PE20140132A1 (es) | Anticuerpo anti-receptor de il-6 | |
| PE20120429A1 (es) | Proteinas de enlace de miostatina | |
| PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
| PE20221263A1 (es) | Agentes de union a ilt3 y metodos de uso de los mismos | |
| AR071510A1 (es) | Anticuerpos anti- factor d humanizados y sus usos | |
| BR112019011988A2 (pt) | anticorpo anti-cd73 humana | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| PE20231851A1 (es) | Proteinas que se unen a nkg2d, cd16 y clec12a | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| PE20110413A1 (es) | Anticuerpos neutralizantes de la glicoproteina b de citomegalovirus humano | |
| PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
| PE20110802A1 (es) | Un anticuerpo antagonista de pcsk9 | |
| PE20161390A1 (es) | Anticuerpos multiespecificos | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| PE20190975A1 (es) | Novela cd47 anticuerpos monoclonales y sus usos | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| PE20180499A1 (es) | Anticuerpos de union a tau | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| ES2570853T3 (es) | Moléculas de anticuerpo humanizadas específicas para IL-31 |